Cargando…

Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors †

Targeting DNA damage and response (DDR) pathway has become an attractive approach in cancer therapy. The key mediators involved in this pathway are ataxia telangiectasia-mutated kinase (ATM) and ataxia telangiectasia-mutated, Rad3-related kinase (ATR). These kinases induce cell cycle arrest in respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaik, Althaf, Bhakuni, Rashmi, Kirubakaran, Sivapriya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102578/ https://www.ncbi.nlm.nih.gov/pubmed/29695073 http://dx.doi.org/10.3390/molecules23050992

Ejemplares similares

Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
por: Amin, Anubhav G., et al.
Publicado: (2021)

High yield bacterial expression, purification and characterisation of bioactive Human Tousled-like Kinase 1B involved in cancer
por: Bhoir, Siddhant, et al.
Publicado: (2018)

Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
por: Francipane, Maria Giovanna, et al.
Publicado: (2013)

Crystal structure and Hirshfeld surface analysis of ethyl 5-phenylisoxazole-3-carboxylate
por: Shaik, Althaf, et al.
Publicado: (2017)

Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents
por: Frasinyuk, Mykhaylo, et al.
Publicado: (2022)

Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
por: Waetzig, Rebecca, et al.
Publicado: (2021)

MDC1 depletion promotes cisplatin induced cell death in cervical cancer cells
por: Singh, Neeru, et al.
Publicado: (2020)

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
por: Park, Seohyun, et al.
Publicado: (2016)

Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection
por: Juvale, Kapil, et al.
Publicado: (2019)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Molecular docking of potential inhibitors with the mTOR protein
por: Fathima, JH Shazia, et al.
Publicado: (2021)

Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
por: Hu, Yi, et al.
Publicado: (2020)

Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes
por: Xu, Song, et al.
Publicado: (2017)

Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells
por: Atkin, Jane, et al.
Publicado: (2014)

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
por: Nasr, Arash Boroumand, et al.
Publicado: (2015)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
por: Du, Wushuang, et al.
Publicado: (2021)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors
por: Ranjbar, Sara, et al.
Publicado: (2018)

Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse
por: Vogel, Kara R, et al.
Publicado: (2015)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

A cell-based chemical-genetic screen for amino acid stress response inhibitors reveals torins reverse stress kinase GCN2 signaling
por: Brüggenthies, Johanna B., et al.
Publicado: (2022)

Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
por: Zapevalova, Maria V., et al.
Publicado: (2022)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Design, Synthesis and Characterization of a Highly Effective Inhibitor for Analog-Sensitive (as) Kinases
por: Klein, Michael, et al.
Publicado: (2011)

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
por: Mallya, Sharmila, et al.
Publicado: (2014)

Three generations of mTOR kinase inhibitors in the activation of the apoptosis process in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2023)

Transcriptomic Analysis of the Effect of Torin-2 on the Central Nervous System of Drosophila melanogaster
por: Vershinina, Yulia S., et al.
Publicado: (2023)

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2016)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iumpo5c7d52pto7m9k728uq9qd